SCHEMBL1338157

SCHEMBL1338157

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(-c4csc(COC(=O)C5CC5)n4)ccc3n(C)c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ PARP1 P09874 2/20 0.36
▸ MAPT P10636 2/20 0.35
▸ GAA P10253 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ APEX1 P27695 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ EIF4E P06730 1/20 0.35
▸ HPSE Q9Y251 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ GABRA1 P14867 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA5 P31644 1/20 0.34
▸ TRPA1 O75762 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1336992 0.88 RAB9A (0.55) NPC1RAB9ATDP1L3MBTL1PARP1
SCHEMBL1339438 0.87 GABRA1 (0.37) NPC1RAB9ATDP1L3MBTL1GAA
SCHEMBL1338539 0.87 L3MBTL1 (0.37) NPC1RAB9ATDP1L3MBTL1GAA
SCHEMBL1337288 0.86 GABRA1 (0.41) NPC1RAB9ATDP1L3MBTL1MAPT
SCHEMBL1339161 0.85 EIF4E (0.39) NPC1RAB9AGAAKDM4EEIF4E
SCHEMBL1337140 0.84 CNR1 (0.36) NPC1RAB9ATDP1L3MBTL1GAA
SCHEMBL1339436 0.84 EIF4E (0.38) NPC1RAB9AGAAKDM4EEIF4E
SCHEMBL1339047 0.83 EIF4E (0.37) NPC1RAB9AGAAKDM4EEIF4E
SCHEMBL1338822 0.83 PARP1 (0.37) NPC1RAB9APARP1GAAKDM4E
SCHEMBL4716844 0.82 EIF4E (0.37) NPC1RAB9AGAAKDM4EEIF4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 NPC1 428/4885RAB9A 2067/4885TDP1 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback